PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2401/4/11 Meda ⭐ Case of the Week

Anonymous v Meda: Promotion of Rhinolast (AUTH/2401/4/11) β€” No breach (outwith scope of the Code)

PMCPA case AUTH/2401/4/11 (Anonymous v Meda) about promotion of Rhinolast. The matter was ruled outwith the scope of the ABPI Code; no…

2018
CASE
AUTH/3050/6/18 AbbVie

AbbVie: complaint about Synagis discussion at BPD Masterclass (AUTH/3050/6/18) – no breach

Anonymous HCP alleged AbbVie rep interrogated clinicians about prescribing and immunising twins outside JCVI guidance and licence at a BPD Masterclass. Panel…

2018
CASE
AUTH/3127/12/18 Merck Sharp & Dohme

MSD voluntary admission: Keytruda congress pillar ad lacked prescribing information and wasn’t certified (AUTH/3127/12/18)

At a UK melanoma congress, organisers mistakenly printed a digital Keytruda app ad onto a pillar. The print lacked prescribing information and…

2016
CASE
AUTH/2907/11/16 Takeda

Takeda: Clinical trial disclosure (Vipidia) β€” No breach, outwith scope (AUTH/2907/11/16)

PMCPA case AUTH/2907/11/16 (Director v Takeda) concerning clinical trial disclosure for Vipidia. Outcome: No breach and matter was outwith the scope of…

2019
CASE
AUTH/3270/10/19 Bayer

Bayer: Xarelto public website invitation to contact medical information breached high standards (AUTH/3270/10/19)

PMCPA found Bayer’s Xarelto site did not promote to the public, but a patient/public page invited people to contact medical information for…

2020
CASE
AUTH/3341/5/20 GlaxoSmithKline ⭐ Case of the Week

GSK voluntary admission: Avamys digital banners had illegible non-proprietary name (AUTH/3341/5/20)

GSK admitted two Avamys online banner ads had a non-proprietary name that was not readily readable in the HTML files and not…

2019
CASE
AUTH/3228/7/19 Ipsen

Merz v Ipsen: Dysport β€˜long-lasting effect’ campaign found misleading on appeal (AUTH/3228/7/19)

After inter-company dialogue, Ipsen’s Dysport messaging (β€˜a toxin with a long-lasting effect’) was held to imply an unsubstantiated duration advantage. Appeal Board…

2020
CASE
AUTH/3339/4/20 Accord

Accord breached ABPI Code after LinkedIn post described POMs as β€œvital COVID-19 medicines” (AUTH/3339/4/20)

An employee complaint upheld after Accord’s public LinkedIn post referred positively to three prescription-only medicines as β€œvital COVID-19 medicines”, amounting to promotion…

2019
CASE
Reckitt Benckiser

Reckitt Benckiser: Pulse Daily email linked to β€˜educational hub’ that promoted Gaviscon for prescription and used β€˜gets to work instantly’ claim

Pulse Daily email linked to a sponsored β€˜education hub’ that the Panel said promoted Gaviscon for prescription. Breaches included disguised promotion, unclear…

2020
CASE
AUTH/3357/5/20 Colonis Pharma

AUTH/3357/5/20: Complainant v Colonis Pharma Ltd – website product pages alleged to advertise POMs to the public (No breach)

Anonymous complainant alleged Colonis’ public website promoted prescription-only medicines. Panel found the pages were non-promotional reference information with no product claims; no…

2020
CASE
AUTH/3389/9/20 Sandoz ⭐ Case of the Week

Sandoz: POM ad visible to the public after journal mailed in transparent wrapper (AUTH/3389/9/20)

A Reletrans (buprenorphine) journal cover outsert became visible when ~3,300 copies were mailed in transparent polywrap. PMCPA ruled promotion of a POM…

2020
CASE
AUTH/3407/10/20 Pharmasure

AUTH/3407/10/20: Pharmasure breached undertaking by leaving Meriofert superiority-style claims on UK website

After giving an undertaking to stop using misleading Meriofert vs Menopur claims, Pharmasure left similar claims live on its UK website. PMCPA…

2019
CASE
Jazz Pharmaceuticals

Jazz Pharmaceuticals: Sunosi websiteβ€”mobile prescribing information not sufficiently prominent (Clause 4.6) and high standards breach (Clause 9.1)

Complaint about Sunosi website links, mobile prescribing info and dosing claim. Panel found no breach for external-link clarity or dosing claim, but…

2021
CASE
AUTH/3470/2/21 GlaxoSmithKline

AUTH/3470/2/21: GlaxoSmithKline – Seretide digital banner ad (no breach)

Complaint alleged a Seretide Evohaler banner claim was misleading on age/indication and that β€œPI” was unclear. PMCPA ruled no breach across all…

2020
CASE
AUTH/3405/10/20 Leo

LEO: Global YouTube content, UK scope and missing mandatory information for tinzaparin symposium video (AUTH/3405/10/20)

Complaint about 60 videos on LEO’s Global YouTube. Most out of UK Code scope, but breaches found for an HCP symposium video…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training